Therapeutic Response

not BCR::ABL1 status confers therapeutic sensitivity to Imatinib in patients with Acute Lymphoblastic Leukemia.

Statements

Source and description
Glivec (imatinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy.
Glivec (imatinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized imatinib as a monotherapy treatment for adult patients with relapased or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).